Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
New England Journal of Medicine2005Vol. 352(1), pp. 29–38
Citations Over TimeTop 1% of 2005 papers
Steven E. Nissen, E. Murat Tuzcu, Paul Schoenhagen, Tim Crowe, William J. Sasiela, John Tsai, John Orazem, Raymond D. Magorien, Charles O’Shaughnessy, Peter Ganz
Abstract
For patients with coronary artery disease, the reduced rate of progression of atherosclerosis associated with intensive statin treatment, as compared with moderate statin treatment, is significantly related to greater reductions in the levels of both atherogenic lipoproteins and CRP.
Related Papers
- → Trends in Statin Use 2009–2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol(2018)46 cited
- → The relationship and diagnostic value of C-reactive protein (CRP) and high-sensitivity- reactive protein (hsCRP) for myocardial infarction(2011)4 cited
- → Abstract 072: Statin Eligibility And Use For Primary Prevention Among US Adults Across Strata Of Atherosclerotic Cardiovascular Disease Risk(2022)1 cited
- Abstract 15219: Statin Decision-Making Since the 2013 AHA/ACC Cholesterol Guidelines: Do Clinicians Do What They Say?(2017)